Alvotech Increases Submissions Efficiency with Continuous Publishing

Alvotech, an Iceland-based biosimilars company, implemented Veeva Submissions Publishing to handle rapidly growing regulatory submission volume across its insulin, vaccine, and monoclonal antibody pipeline. Shifting from linear to continuous publishing -- running downstream tasks in parallel with upstream planning -- let the team catch errors earlier. The page reports a 40% efficiency increase year-over-year, submission output scaling ninefold since 2020, and four major biologic license applications submitted to the EMA and FDA within weeks of going live in June 2024.

Veeva Systems is the dominant CRM and content platform in pharma commercial, regulatory, clinical and quality operations, now shipping AI agents directly inside those same production systems.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.